Cardiovascular
Cardiovascular diseases encompass a wide range of conditions including heart attack, heart failure, thrombosis, pulmonary embolism, and aneurysm. Laboratory testing provides important information about heart and blood vessel health through various tests. These data help assess cardiovascular disease risk, diagnose heart or vascular conditions, choose appropriate treatment, and monitor therapy.
In vitro diagnostics
Examples illustrate the added value of laboratory tests in detecting, diagnosing, monitoring, and treating cardiovascular diseases.
In vitro diagnostics
-
Heart attack
During a heart attack, a coronary artery becomes blocked, causing oxygen deficiency in (parts of) the heart. This leads to heart tissue damage, causing substances to be released from affected heart cells into the blood. These include troponin and creatine kinase (CK-MB), two characteristic heart proteins. Both are used to diagnose a heart attack.
Troponin test
Troponin is a protein that normally enables heart muscle contraction. When the heart and heart tissue are healthy, blood troponin levels are low. During a heart attack, troponin is released. This becomes measurable in the blood after three hours and remains elevated for two weeks after the heart attack. The troponin test is used to diagnose heart attacks in people who arrive at Emergency Cardiac Care (ECC) with chest pain. However, only about twenty percent of these patients actually have a heart attack. To prevent unnecessary ECC referrals, the test is now available as a high-sensitivity troponin point-of-care test. This highly sensitive test can determine troponin levels at the patient's location. Combined with a risk score, the healthcare provider can immediately decide whether someone with chest pain needs to be admitted.
CK-MB test
Creatine kinase (CK) is an enzyme that plays an important role in cellular energy supply in the heart, brain, and muscles. CK-MB is a form of an enzyme primarily found in heart muscle. It is released when heart tissue is damaged. In an acute heart attack, CK-MB becomes measurable in the blood after three to six hours. Peak values are reached after twelve to twenty hours. After that, values return to normal. The CK-MB test is less specific than the troponin test.
-
Heart failure
In heart failure, the heart doesn't pump blood effectively, causing organs and muscles to receive insufficient oxygen and nutrients. Early detection of heart failure is very important. While the condition cannot be cured, treatment options are available. Heart failure can be detected through a blood test that measures two specific proteins: BNP and NT-proBNP, both indicating poor heart pump function.
BNP and NT-proBNP
When the heart muscle experiences increased stress, BNP (Brain-type Natriuretic Peptide) is released from heart muscle cells. BNP causes blood vessels to dilate, reducing the heart strain. Along with BNP, the physiologically inactive byproduct NT-proBNP is also released. Blood levels of both compounds provide insight into heart failure (severity). Because multiple causes can lead to elevated BNP and NT-proBNP, this test's strength lies primarily in ruling out heart failure when there is strong clinical suspicion of the condition. The test is also suitable for following up medication effects (monitoring) and estimating heart failure risk (prognosis).
-
Thrombosis
In thrombosis, a blood vessel becomes blocked by a blood clot. When the clot blocks a vein, it's called venous thromboembolism (VTE). This often occurs in the legs (deep vein thrombosis). A clot can break off and travel to the lungs (pulmonary embolism). Deep vein thrombosis (DVT) occurs in the deeper veins.
D-dimer test
Diagnosing thrombosis can be challenging. Along with ultrasound and imaging diagnostics, blood testing plays a complementary role through the D-dimer test. D-dimers are released during blood clot breakdown. When these compounds are detected in the blood, it indicates the presence (current or recent) of a clot. The D-dimer test is quick and simple but not specific. A positive result requires follow-up testing to confirm venous thromboembolism (VTE); a negative result can rule out VTE. With a point-of-care D-dimer test, primary care physicians can rule out VTE when thrombosis is suspected.
Blood coagulation test
Patients with an increased risk of thrombosis are treated with anticoagulants (blood thinners). Dosing requires precise monitoring: too much anticoagulant increases the risk of severe bleeding, too little leads to blood clots. Monitoring blood coagulation status is crucial for proper dose adjustment. Blood clotting time can be determined using the PT test (prothrombin time) and/or the APTT test (activated partial thromboplastin time). Anticoagulation medication can be adjusted based on test results. The test is also available as a home test, allowing patients to monitor their blood coagulation values and adjust medication themselves.
- Home /
- Laboratory Medicine /
- Cardiovascular
Added value
Patients
- More certainty
- Better treatment
- Higher quality of life
- More (healthy) life years
Healthcare system
- Cost savings
- Less absenteeism
- Less burdensome for healthcare
- Healthier society
Medical Professionals
- Valuable diagnostic information
- Reliable basis for clinical decisions
- More personalized treatments
- Insight into the effectiveness of treatment